Better Yields at Reduced Costs
Athens - The Hellenic Innovation Centre presented a new technology in October that enables the production of high-grade pharmaceutical raw material like Inter-feron- and - , Erythropoietin, FSH, and HGH, without unwanted properties but with better production yields and at reduced costs.
The main innovation of the technology is its ability to select exklusively coding DNA sequences without having any redundant DNA material in the working cDNA strand. This means that precisely designed recombinant proteins can be created which are accurately tailored to the exact requirements of the production of genetic raw material to produce more effective recombinant phar-maceuticals in less time and at lower costs than is currently possible. The tech-nology also enables to ease design and create chimeric (fused) molecules of DNA expressing the characteristics of two entirely different proteins in a single chain or even expressing only the active centres of these proteins.
The Hellenic Innovation Centre is looking for license agreements, joint venture agreements and manufacturing agreements with pharmaceutical companies.
Kiki Aliakrida, eMail: email@example.com